{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:49:27Z","timestamp":1775058567866,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To determine the effectiveness of quick starting combined oral contraception (COC) contain 2.5\u2009mg nomegestrol acetate and 1.5\u2009mg estradiol (NOMAC\/E2) comparing with 0.075\u2009mg gestodene and 0.02\u2009mg ethinyl estradiol (GS\/EE) on ovarian ovulation inhibition rate, we conducted a non-inferiority randomized controlled trial involving 69 healthy female volunteers aged 18\u201340 years who had normal menstrual history and were randomized at a 2:1 ratio to take one pack of COC containing either NOMAC\/E2 (study group) or GS\/EE (control group) starting on menstrual cycle Day7\u20139. The ovarian activity was assessed by using Hoogland and Skouby grading. Forty-six and 23 participants were randomized to NOMAC\/E2 and GS\/EE groups, respectively. Baseline characteristics were similar between groups. No significant difference was observed between the study and control groups for ovulation inhibition rate (93.4% vs. 95.6%, risk difference: \u20132.2%, 95% CI: \u201313.1, 8.8), ovarian quiescence rate (91.2% vs. 91.2%, P\u2009=\u20091.000), persistent cyst rate (2.2% vs. 4.4%, <jats:italic>P<\/jats:italic>\u2009=\u20091.000), and ovulation rate (6.6% vs. 4.4%, <jats:italic>P<\/jats:italic>\u2009=\u20091.000). Quick starting COC during day7\u20139 of menstrual cycle can inhibit ovulation for more than 90%. The quick starting NOMAC\/E2 is non-inferior to GS\/EE for preventing ovulation and suppressing follicular growth.<\/jats:p>","DOI":"10.1038\/s41598-020-65642-5","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T10:02:27Z","timestamp":1590746547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effectiveness of quick starting oral contraception containing nomegestrol acetate and 17-\u03b2 estradiol on ovulation inhibition: A randomized controlled trial"],"prefix":"10.1038","volume":"10","author":[{"given":"Preeyaporn","family":"Jirakittidul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surasak","family":"Angsuwathana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-9249","authenticated-orcid":false,"given":"Manee","family":"Rattanachaiyanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thunyada","family":"Thiampong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanon","family":"Neungton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjaphorn","family":"Chotrungrote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"65642_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.beem.2012.11.004","volume":"27","author":"S Christin-Maitre","year":"2013","unstructured":"Christin-Maitre, S. History of oral contraceptive drugs and their use worldwide. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 3\u201312, https:\/\/doi.org\/10.1016\/j.beem.2012.11.004 (2013).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"65642_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.rbmo.2016.07.010","volume":"33","author":"S D\u2019Arpe","year":"2016","unstructured":"D\u2019Arpe, S. et al. Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review. Reprod. Biomed. Online 33, 436\u201348, https:\/\/doi.org\/10.1016\/j.rbmo.2016.07.010 (2016).","journal-title":"Reprod. Biomed. Online"},{"key":"65642_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.contraception.2011.04.009","volume":"84","author":"J Endrikat","year":"2011","unstructured":"Endrikat, J., Gerlinger, C., Richard, S., Rosenbaum, P. & Dusterberg, B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception 84, 549\u201357, https:\/\/doi.org\/10.1016\/j.contraception.2011.04.009 (2011).","journal-title":"Contraception"},{"key":"65642_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.contraception.2017.01.006","volume":"95","author":"C Morroni","year":"2017","unstructured":"Morroni, C., Findley, M. & Westhoff, C. Does using the \u201cpregnancy checklist\u201d delay safe initiation of contraception? Contraception 95, 331\u20134, https:\/\/doi.org\/10.1016\/j.contraception.2017.01.006 (2017).","journal-title":"Contraception"},{"key":"65642_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6504a1","volume":"4","author":"KM Curtis","year":"2016","unstructured":"Curtis, K. M. et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm. Rep. 65 No. RR- 4, 1\u201366, https:\/\/doi.org\/10.15585\/mmwr.rr6504a1 (2016).","journal-title":"MMWR Recomm. Rep. 65 No. RR-"},{"key":"65642_CR6","unstructured":"FSRH Quick Starting Contraception. April 2017. Available from, www.fsrh.org\/standards-andguidance\/current-clinical-guidance\/quick-starting-contraception\/ [accessed 8 Jun 2017]."},{"key":"65642_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.contraception.2012.09.010","volume":"87","author":"D Brahmi","year":"2013","unstructured":"Brahmi, D. & Curtis, K. M. When can a woman start combined hormonal contraceptives CHCs ? A systematic review. Contraception 87, 524\u201338, https:\/\/doi.org\/10.1016\/j.contraception.2012.09.010 (2013).","journal-title":"Contraception"},{"key":"65642_CR8","first-page":"442","volume":"86","author":"S Sitavarin","year":"2003","unstructured":"Sitavarin, S., Jaisamrarn, U. & Taneepanichskul, S. A randomized trial on the impact of starting day on ovarian follicular activity in very low dose oral contraceptive pills users. J. Med. Assoc. Thai 86, 442\u20138 (2003).","journal-title":"J. Med. Assoc. Thai"},{"key":"65642_CR9","first-page":"177","volume":"99","author":"JL Schwartz","year":"2002","unstructured":"Schwartz, J. L. CM, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet. Gynecol. 99, 177\u201382 (2002).","journal-title":"Obstet. Gynecol."},{"key":"65642_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0010-7824(86)80005-1","volume":"33","author":"DR Taylor","year":"1986","unstructured":"Taylor, D. R., Anthony, F. W. & Dennis, K. J. Suppression of ovarian function by Microgynon 30 in day 1 and day. 5 \u201cstarters\u201d. Contraception 33, 463\u201371 (1986).","journal-title":"Contraception"},{"key":"65642_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0015-0282(16)59407-2","volume":"48","author":"S Killick","year":"1987","unstructured":"Killick, S., Eyong, E. & Elstein, M. Ovarian follicular development in oral contraceptive cycles. Fertil. Steril. 48, 409\u201313 (1987).","journal-title":"Fertil. Steril."},{"issue":"7","key":"65642_CR12","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/humrep\/dev115","volume":"30","author":"ST Cameron","year":"2015","unstructured":"Cameron, S. T., Berger, C., Michie, L., Klipping, C. & Gemzell-Danielsson, K. The effects on ovarian activity of ulipristal acetate when \u2018quickstarting\u2019 a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum. Reprod. 30(7), 1566\u201372, https:\/\/doi.org\/10.1093\/humrep\/dev115 (2015).","journal-title":"Hum. Reprod."},{"issue":"1","key":"65642_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.fertnstert.2005.12.046","volume":"86","author":"AR Baerwald","year":"2006","unstructured":"Baerwald, A. R., Olatunbosun, O. A. & Pierson, R. A. Effects of oral contraceptives administered at defined stages of ovarian follicular development. Fertil. Steril. 86(1), 27\u201335, https:\/\/doi.org\/10.1016\/j.fertnstert.2005.12.046 (2006).","journal-title":"Fertil. Steril."},{"issue":"1","key":"65642_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.contraception.2010.11.004","volume":"84","author":"R Burkman","year":"2011","unstructured":"Burkman, R., Bell, C. & Serfaty, D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception 84(1), 19\u201334, https:\/\/doi.org\/10.1016\/j.contraception.2010.11.004 (2011).","journal-title":"Contraception"},{"issue":"4","key":"65642_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.maturitas.2012.01.007","volume":"71","author":"X Ruan","year":"2012","unstructured":"Ruan, X., Seeger, H. & Mueck, A. O. The pharmacology of nomegestrol acetate. Maturitas 71(4), 345\u201353, https:\/\/doi.org\/10.1016\/j.maturitas.2012.01.007 (2012).","journal-title":"Maturitas"},{"issue":"1","key":"65642_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beem.2012.09.004","volume":"27","author":"R Sitruk-Ware","year":"2013","unstructured":"Sitruk-Ware, R. & Nath, A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best. Pract. Res. Clin. Endocrinol. Metab. 27(1), 13\u201324, https:\/\/doi.org\/10.1016\/j.beem.2012.09.004 (2013).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"6","key":"65642_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.contraception.2012.12.011","volume":"87","author":"FZ Stanczyk","year":"2013","unstructured":"Stanczyk, F. Z., Archer, D. F. & Bhavnani, B. R. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 87(6), 706\u201327, https:\/\/doi.org\/10.1016\/j.contraception.2012.12.011 (2013).","journal-title":"Contraception"},{"issue":"6","key":"65642_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.steroids.2011.02.002","volume":"76","author":"AO Mueck","year":"2011","unstructured":"Mueck, A. O. & Sitruk-Ware, R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76(6), 531\u20139, https:\/\/doi.org\/10.1016\/j.steroids.2011.02.002 (2011).","journal-title":"Steroids"},{"key":"65642_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/OAJC.S61942","volume":"6","author":"H Akintomide","year":"2015","unstructured":"Akintomide, H. & Panicker, S. Nomegestrol acetate\/17-beta estradiol: a review of efficacy, safety, and patient acceptability. Open. Access. J. Contracept. 6, 77\u201386, https:\/\/doi.org\/10.2147\/OAJC.S61942 (2015).","journal-title":"Open. Access. J. Contracept."},{"issue":"7","key":"65642_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/CAD.0000000000000050","volume":"25","author":"L Del Pup","year":"2014","unstructured":"Del Pup, L. et al. Nomegestrol acetate\/estradiol hormonal oral contraceptive and breast cancer risk. Anticancer. Drugs 25(7), 745\u201350, https:\/\/doi.org\/10.1097\/CAD.0000000000000050 (2014).","journal-title":"Anticancer. Drugs"},{"issue":"6","key":"65642_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","volume":"47","author":"HKSS Hoogland","year":"1993","unstructured":"Hoogland, H. K. S. S. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 47(6), 583\u201390 (1993).","journal-title":"Contraception"},{"issue":"1","key":"65642_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/humupd\/dmr039","volume":"18","author":"AR Baerwald","year":"2012","unstructured":"Baerwald, A. R., Adams, G. P. & Pierson, R. A. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum. Reprod. update 18(1), 73\u201391 (2012).","journal-title":"Hum. Reprod. update"},{"issue":"11","key":"65642_CR23","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1517\/14728222.2015.1051305","volume":"19","author":"SK Gupta","year":"2015","unstructured":"Gupta, S. K., Malik, A. & Arukha, A. P. Ovarian and oocyte targets for development of female contraceptives. Expert. Opin. therapeutic targets 19(11), 1433\u201346. (2015).","journal-title":"Expert. Opin. therapeutic targets"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65642-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65642-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65642-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:53:08Z","timestamp":1670327588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65642-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65642"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65642-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"12 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and\/or distribute the drugs, devices, or materials described in this report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8782"}}